Home LiteratureArticle Details
PMID: 39013258 Published · ppublish English

Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers.

Pathology, research and practice ·Vol. 260 ·2024-08-00

Akın D, Kahraman Çeti N N, Erdoğdu İH, Öztürk H, Meteoğlu İ

Abstract

The primary tumor and it's metastases show heterogeneity in molecular studies for targeted therapies in Non-Small Cell Lung Cancer(NSCLC), the leading cause of cancer-related deaths worldwide. The study aimed to identify somatic mutations in biopsies from NSCLC patients' metastatic organs using Next-Generation Sequencing(NGS) and examine their association with clinicopathological parameters. The study included 128 NSCLC patients and, NGS was performed on tumor biopsies from different metastatic organs at Molecular Pathology laboratory of the Department of Medical Pathology in Aydın Adnan Menderes University Faculty of Medicine. The age, gender, histopathological diagnoses, metastatic organs, smoking and mutation status were all recorded, along with the analysis results of 72 genes and 4149 primers in the panel of the NGS system. 53.9 % of the cases had a history of smoking and patients with brain metastases had a higher smoking rate(p=0.000). The most common occurrence(39.8 %) was lymph node metastasis, followed by brain(19.5 %). There was a strong correlation between mutation presence and metastasis in the liver(p=0.012), bone(p=0.002), and pleura(p=0.008). Smokers had a higher frequency of KRAS(p=0.000) and TP53(p=0.001) mutations. Brain metastases showed a statistically significant NF1 mutation(p=0.001), while the liver exhibited a significant BRAF mutation(p=0.000). NF1-TP53, PTEN-TP53 and NF1-PTEN were the most common concomitant mutations and, the brain was the most common metastatic organ in which they occurred. Our results suggest prizing assessing detected mutations, in the prediction, follow-up and management of metastases, especially in patients with lung adenocarcinoma. The assessment also needs to consider the tumor's mutation status in metastatic organs. New therapeutic agents targeting NF1 mutations will be available in the future to treat NSCLC, especially in metastases.

Keywords
Adenocarcinoma Molecular Mutations Next-Generation Sequencing Non-small cell lung cancer
MeSH 主题词
Humans Carcinoma, Non-Small-Cell Lung/genetics,pathology,secondary Lung Neoplasms/genetics,pathology Male Female High-Throughput Nucleotide Sequencing Middle Aged Mutation Aged Adult DNA Mutational Analysis Brain Neoplasms/genetics,secondary Biomarkers, Tumor/genetics Lymphatic Metastasis/genetics,pathology
Article Info
Journal
Pathology, research and practice
Abbr.
Pathol Res Pract
ISSN
1618-0631
Corresponding email
Published
2024-08-00
Language
English
Country/Region
Germany
NLM ID
7806109
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com